乙型肝炎病毒(HBV)感染是导致肝硬化和肝癌的重要因素,但长期接受拉米夫定治疗的患者会产生耐药变异,一般服用拉米夫定>6～9个月,部分患者可发生耐药变异,并随治疗时间延长而突变率逐渐增高。据文献报道,一般治疗 Hepatitis B virus (HBV) infection is an important factor leading to cirrhosis and liver cancer, but long-term patients receiving lamivudine will produce resistance mutations, the general use of lamivudine> 6 to 9 months, some patients may be Mutation resistance occurred, and with the extension of treatment time, the mutation rate gradually increased. According to the literature, the general treatment